Breast Cancer Awareness Month raises awareness, but it doesn’t tell the whole story. In France, an integrated model—from research to industry—is transforming breast cancer care with a year-round impact.
Innovations That Redefine Standards
Targeted Therapies: ADCs Push Boundaries
At the ESMO 2025 congress, antibody-drug conjugates (ADCs) like trastuzumab deruxtecan showed superior efficacy compared to T-DM1, even in early treatment. These advances are changing surgical and post-operative protocols. The HAS acknowledges these improvements (ASMR III), and French data (EPI-PHARE) confirms their tolerability, especially regarding interstitial lung disease.
Precision Medicine: A Personalized Approach
France aims to tailor therapy to each patient. Molecular profiling and biomarkers are central to this approach. Advocates are calling for research to better reflect female-specific biology and correct historical biases.
From Lab to Bedside: Curie, Unicancer, ARC
At the Curie Institute, liquid biopsies help anticipate relapses. A study on triple-negative breast cancer explores monitoring through a simple blood test.
“We’re developing tools that can identify transforming breast cells before they become tumors.”
— Melissa Saichi, Curie Institute
Unicancer is conducting de-escalation trials (RIBOLARIS), advancing tumor DNA monitoring (TRAKER), and leveraging data through ESME. The ARC Foundation supports research and engages the public with events like the Triathlon des Roses.
AI and Data: Anticipating and Personalizing Care
The Curie–Google alliance is developing models to improve diagnosis and predict treatment responses. ctDNA programs enable ultra-early relapse detection and guide targeted de-escalation strategies.
Testing Before Treating: The Montpellier–CNRS Example
Montpellier University Hospital and CNRS have simplified BH3 profiling, allowing tumor sensitivity to treatment to be assessed in under 24 hours. This functional, hospital-based test shows promise for quickly personalizing therapeutic combinations.
Bioproduction: Ensuring Access to Treatments
Thanks to the France 2030 strategy, France ranks second in Europe for biotherapies, with 86 funded projects and a goal to produce 60 biomedicines by 2030. This secures supply, shortens delays, and stabilizes costs.
What This Means for Patients
- Earlier treatments thanks to ADCs
- More precise monitoring via tumor DNA
- Personalized care pathways with functional tests
- Safer access through bioproduction
Conclusion
France is reinventing the fight against breast cancer by connecting research, clinical trials, data, AI, and production. This model improves survival rates, reduces toxicity, and speeds up access to care.
“Breast cancer is curable in 9 out of 10 cases when detected early.”
